Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acceleration Therapeutics' AT-101 reclassified by the FDA

This article was originally published in Clinica

Executive Summary

The US FDA has asked Acceleration Therapeutics to reclassify its power exercise device, AT-101, following the discovery that it no longer meets FDA class 1 (exempt) requirements. The company said the matter was of serious concern to its business and is unable to resume selling the product, a full body vibrating mattress, until it receives a 510(k) allowance letter from the FDA.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts